NBIX

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Peers: VRTX REGN BIIB GILD INCY ALNY EXEL IONS SAGE ACAD

| Held by: IJH VTI VB VBK VXF XBI MDY IBB IWP IJK

Index	-	P/E	33.90	EPS (ttm)	4.19	Insider Own	2.71%	Shs Outstand	99.70M	Perf Week	-4.69%
Market Cap	14.15B	Forward P/E	20.10	EPS next Y	7.06	Insider Trans	-7.74%	Shs Float	97.00M	Perf Month	3.60%
Enterprise Value	13.52B	PEG	0.94	EPS next Q	1.90	Inst Own	99.70%	Short Float	4.50%	Perf Quarter	10.57%
Income	428.00M	P/S	5.28	EPS this Y	56.08%	Inst Trans	3.02%	Short Ratio	4.95	Perf Half Y	29.35%
Sales	2.68B	P/B	4.71	EPS next Y	37.54%	ROA	10.97%	Short Interest	4.37M	Perf YTD	4.00%
Book/sh	30.13	P/C	12.70	EPS next 5Y	36.10%	ROE	14.96%	52W High	154.61 -8.18%	Perf Year	14.18%
Cash/sh	11.18	P/FCF	23.86	EPS past 3/5Y	53.21% 53.47%	ROIC	12.47%	52W Low	84.23 68.54%	Perf 3Y	24.69%
Dividend Est.	-	EV/EBITDA	23.18	Sales past 3/5Y	27.61% 24.48%	Gross Margin	98.14%	Volatility	4.32% 2.85%	Perf 5Y	41.76%
Dividend TTM	-	EV/Sales	5.04	EPS Y/Y TTM	11.36%	Oper. Margin	20.64%	ATR (14)	4.25	Perf 10Y	204.57%
Dividend Ex-Date	-	Quick Ratio	3.27	Sales Y/Y TTM	19.61%	Profit Margin	15.95%	RSI (14)	51.63	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	3.38	EPS Q/Q	64.23%	SMA20	0.98%	Beta	0.22	Target Price	174.81
Payout	0.00%	Debt/Eq	0.16	Sales Q/Q	27.78%	SMA50	0.75%	Rel Volume	0.87	Prev Close	143.21
Employees	1800	LT Debt/Eq	0.14	Earnings	Oct 28 AMC	SMA200	12.01%	Avg Volume	882.03K	Price	141.96
IPO	May 23, 1996	Option/Short	Yes / Yes	EPS/Sales Surpr.	27.95% 6.43%	Trades		Volume	764,178	Change	-0.87%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-25	Initiated	Citigroup	Buy	$175
Jul-21-25	Initiated	Truist	Buy	$163
Jul-10-25	Initiated	Goldman	Buy	$182
Apr-15-25	Upgrade	Needham	Hold → Buy	$138
Apr-14-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$137
Feb-11-25	Initiated	Deutsche Bank	Hold	$138
Oct-10-24	Resumed	Raymond James	Outperform	$155
Aug-29-24	Upgrade	Piper Sandler	Neutral → Overweight	$131 → $159
Apr-24-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$140 → $170
Dec-13-23	Resumed	Citigroup	Neutral	$127
Dec-12-23	Initiated	Deutsche Bank	Buy	$136
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$135 → $140
Aug-21-23	Reiterated	Mizuho	Neutral	$112 → $113
Jul-24-23	Upgrade	SVB Securities	Market Perform → Outperform	$115 → $125
Jul-06-23	Upgrade	BMO Capital Markets	Underperform → Market Perform	$91 → $96
May-04-23	Upgrade	Guggenheim	Neutral → Buy	$145
Mar-30-23	Upgrade	Canaccord Genuity	Hold → Buy	$124 → $132
Mar-03-23	Upgrade	Evercore ISI	In-line → Outperform	$130
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$120 → $130
Nov-14-22	Downgrade	Evercore ISI	Outperform → In-line	$140 → $130

Show Previous Ratings

Oct-30-25 04:15PM	Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
03:21PM	Neurocrine Biosciences Inc (NBIX) Q3 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
01:13PM	Earnings roundup: Alnylams down day, Neurocrines head scratch and Biogens low quality win (BioPharma Dive)
09:49AM	Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
Oct-29-25 04:14PM	Why Neurocrine Stock Was Spooked Despite Its Big Quarterly Beat (Investor's Business Daily) -6.35%
09:03PM	Loading…
Oct-28-25 09:03PM	Neurocrine Biosciences Beats Estimates But Wall Street Punishes The Stock (24/7 Wall St.)
07:30PM	Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q3 Earnings (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates (Zacks)
04:45PM	Neurocrine Shares Rise, But Pull Back From Steep Gains, On Strong Ingrezza Quarter (Investor's Business Daily)
04:19PM	Neurocrine Bio Surges After Crushing Third-Quarter Expectations (Investor's Business Daily)
04:06PM	Neurocrine: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports Third Quarter 2025 Financial Results (PR Newswire)
Oct-24-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Neurocrine Biosciences (NBIX) is a Great Choice (Zacks)
Oct-23-25 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX) (Zacks)
Oct-22-25 05:15PM	USANA Health Sciences (USNA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
10:00AM	Loading…
10:00AM	United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-21-25 10:00AM	Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-17-25 08:30AM	Neurocrine Biosciences Presents New KINECT 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA (valbenazine) 40 mg Capsules (PR Newswire)
Oct-07-25 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results (PR Newswire)
Oct-06-25 04:05PM	Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise (PR Newswire)
08:30AM	Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA (valbenazine) Capsules for Huntington's Disease Chorea (PR Newswire)
Sep-25-25 09:55AM	Should You be Optimistic on Neurocrine Biosciences (NBIX)? (Insider Monkey)
Sep-24-25 11:40AM	GRFS or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
Sep-23-25 08:30AM	Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden (PR Newswire)
Sep-22-25 08:30AM	Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder (PR Newswire)
Sep-16-25 04:05PM	Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025 (PR Newswire)
02:58PM	What Does Wall Street Think About Neurocrine Biosciences (NBIX)? (Insider Monkey)
Sep-02-25 04:03AM	Neurocrine Biosciences, Inc. (NBIX) Beats Estimates on Neurology Drug Demand, Expands Payer Access (Insider Monkey)
Aug-26-25 04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences in September (PR Newswire)
Aug-20-25 11:40AM	GRFS or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
10:16AM	Loading…
Aug-12-25 10:16AM	Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
Aug-06-25 04:01PM	Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference (PR Newswire)
Jul-31-25 03:32AM	Neurocrine Biosciences Inc (NBIX) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com) -6.24%
Jul-30-25 06:00PM	Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:05PM	Neurocrine: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports Second Quarter 2025 Financial Results (PR Newswire)
Jul-28-25 11:40AM	CPRX vs. NBIX: Which Stock Should Value Investors Buy Now? (Zacks)
Jul-27-25 09:58AM	Neurocrine Biosciences Grows Pipeline While Maintaining Steady Investor Confidence (Insider Monkey)
Jul-25-25 11:28PM	Morgan Stanley Lifts PT on Neurocrine Biosciences (NBIX) to $150 From $148, Keeps Overweight Rating (Insider Monkey)
Jul-24-25 10:00AM	Indivior PLC (INDV) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-23-25 10:00AM	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-15-25 10:57AM	Neurocrine shares new one-year data from trial of Crenessity for CAH (Clinical Trials Arena)
09:00AM	Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition (PR Newswire)
08:30AM	Neurocrine Biosciences Presents New Analysis of CAHtalog Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025 (PR Newswire)
Jul-14-25 04:35PM	Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting (PR Newswire)
08:30AM	Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY (crinecerfont) in Adult Patients, at ENDO 2025 (PR Newswire)
Jul-10-25 11:26PM	Untapped Patient Base, Ingrezza Growth Keep Neurocrine (NBIX) on Guggenheim's Buy List (Insider Monkey)
08:00AM	Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity (Investor's Business Daily)
Jul-09-25 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results (PR Newswire)
Jun-30-25 04:05PM	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist (PR Newswire)
Jun-29-25 08:36AM	3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking (MarketBeat)
Jun-27-25 08:30AM	Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA (valbenazine) Capsules for Huntington's Disease Chorea (PR Newswire)
Jun-23-25 11:40AM	EGO or AEM: Which Is the Better Value Stock Right Now? (Zacks)
11:40AM	CPRX vs. NBIX: Which Stock Is the Better Value Option? (Zacks)
Jun-20-25 08:30AM	Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA (valbenazine) Capsules in Older Adults with Tardive Dyskinesia (PR Newswire)
Jun-17-25 06:20AM	Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? (Zacks)
Jun-12-25 06:20AM	Should You Invest in the SPDR S&P Biotech ETF (XBI)? (Zacks)
Jun-09-25 04:05PM	Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer (PR Newswire)
Jun-03-25 11:40AM	CPRX or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
Jun-02-25 08:30AM	Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO Study Demonstrating INGREZZA (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia (PR Newswire)
May-30-25 04:30PM	Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors (GlobeNewswire)
May-29-25 12:03AM	Neurocrine Biosciences, Inc. (NBIX)'s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched (Insider Monkey)
May-28-25 04:05PM	Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 (PR Newswire)
May-27-25 06:20AM	Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? (Zacks)
May-26-25 06:20AM	Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now? (Zacks)
May-20-25 06:20AM	Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? (Zacks)
May-16-25 08:30AM	Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting (PR Newswire)
08:25AM	Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia (PR Newswire)
May-15-25 04:05PM	Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY (crinecerfont) (PR Newswire)
11:40AM	GRFS or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
May-14-25 04:05PM	Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia (PR Newswire)
May-13-25 03:48PM	Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Ken Griffin's Midcap Stock Picks with Huge Upside Potential (Insider Monkey)
12:07PM	Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
06:20AM	Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar? (Zacks)
May-08-25 08:30AM	Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst Pediatric Study Demonstrating CRENESSITY Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups (PR Newswire)
May-07-25 03:34AM	Why Neurocrine Biosciences, Inc. (NBIX) Skyrocketed On Tuesday (Insider Monkey)
May-06-25 04:40PM	Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug (Investor's Business Daily) +8.36%
04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences in May (PR Newswire)
08:36AM	Q1 2025 Neurocrine Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
08:30AM	Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie Awareness Campaign for People with Tardive Dyskinesia (PR Newswire)
06:20AM	Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now? (Zacks)
03:05AM	Neurocrine Biosciences Inc (NBIX) Q1 2025 Earnings Call Highlights: Strong INGREZZA Sales and ... (GuruFocus.com)
May-05-25 08:33PM	Neurocrine Biosciences, Inc. (NBIX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:30PM	Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates (Zacks)
04:09PM	Neurocrine: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance (PR Newswire)
08:30AM	Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia (PR Newswire)
May-01-25 07:18AM	Neurocrine begins Phase III programme for schizophrenia treatment (Clinical Trials Arena)
Apr-30-25 11:43AM	Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Cliff Asness' Stock Picks with Huge Upside Potential (Insider Monkey)
08:00AM	Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia (PR Newswire)
Apr-29-25 10:01AM	Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Apr-28-25 10:00AM	Neurocrine Biosciences (NBIX) Q1 Earnings Preview: What's in the Cards? (Zacks)
Apr-24-25 04:05PM	Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry (PR Newswire)
Apr-22-25 06:05PM	Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025 (Seeking Alpha)
Apr-16-25 05:51PM	Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity (Seeking Alpha)
Apr-14-25 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results (PR Newswire)
Apr-07-25 11:39AM	Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options (Zacks)
Apr-04-25 08:00AM	Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer (PR Newswire) -7.03%

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GORMAN KEVIN CHARLES	Director	Aug 07 '25	Option Exercise	35.99	106,322	3,826,529	620,918	Aug 11 04:55 PM
GORMAN KEVIN CHARLES	Director	Aug 07 '25	Sale	126.41	106,322	13,440,281	514,596	Aug 11 04:55 PM
KEVIN CHARLES GORMAN	Director	Aug 07 '25	Proposed Sale	128.43	106,322	13,654,934		Aug 07 04:24 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 10 '25	Option Exercise	79.02	457	36,112	5,187	Jul 11 05:15 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 10 '25	Sale	135.00	457	61,695	4,730	Jul 11 05:15 PM
Onyia Jude	Chief Scientific Officer	Jul 09 '25	Option Exercise	84.74	59,819	5,069,062	78,108	Jul 11 05:01 PM
Onyia Jude	Chief Scientific Officer	Jul 09 '25	Sale	130.46	59,819	7,803,688	18,289	Jul 11 05:01 PM
INGRID DELAET	Officer	Jul 10 '25	Proposed Sale	133.51	457	61,014		Jul 10 04:32 PM
Onyia Jude	Chief Scientific Officer	Jul 02 '25	Option Exercise	84.74	20,362	1,725,476	38,651	Jul 07 04:10 PM
Onyia Jude	Chief Scientific Officer	Jul 02 '25	Sale	130.13	20,362	2,649,738	18,289	Jul 07 04:10 PM
JUDE ONYIA	Officer	Jul 02 '25	Proposed Sale	128.00	80,181	10,263,168		Jul 02 04:22 PM
GORMAN KEVIN CHARLES	Director	May 27 '25	Sale	120.38	9,613	1,157,211	514,596	May 29 06:15 PM
KEVIN CHARLES GORMAN	Director	May 27 '25	Proposed Sale	120.18	9,613	1,155,290		May 27 04:38 PM
RASTETTER WILLIAM H	Director	May 22 '25	Option Exercise	0.00	2,869	0	40,360	May 22 06:15 PM
POON CHRISTINE A	Director	May 22 '25	Option Exercise	0.00	1,435	0	1,435	May 22 05:32 PM
Sharp Shalini	Director	May 22 '25	Option Exercise	0.00	1,435	0	2,429	May 22 05:28 PM
SHERWIN STEPHEN A	Director	May 22 '25	Option Exercise	0.00	2,869	0	13,542	May 22 05:26 PM
POPS RICHARD F	Director	May 22 '25	Option Exercise	0.00	2,869	0	34,480	May 22 05:23 PM
MORROW GEORGE J	Director	May 22 '25	Option Exercise	0.00	2,869	0	7,068	May 22 05:20 PM
LYONS GARY A	Director	May 22 '25	Option Exercise	0.00	1,435	0	120,482	May 22 05:18 PM
Norwalk Leslie V	Director	May 22 '25	Option Exercise	0.00	1,435	0	2,429	May 22 05:14 PM
Mercier Johanna	Director	May 22 '25	Option Exercise	0.00	1,435	0	3,535	May 22 05:12 PM
Cooke Julie	Chief Human Resources Officer	May 16 '25	Option Exercise	61.82	6,468	399,852	26,858	May 20 04:43 PM
RASTETTER WILLIAM H	Director	May 05 '25	Option Exercise	42.76	30,000	1,282,800	67,491	May 07 07:05 PM
RASTETTER WILLIAM H	Director	May 05 '25	Sale	110.20	30,000	3,305,952	37,491	May 07 07:05 PM
WILLIAM H. RASTETTER	Officer	May 05 '25	Proposed Sale	109.68	30,000	3,290,400		May 05 04:40 PM
Cooke Julie	Chief Human Resources Officer	Feb 13 '25	Option Exercise	0.00	2,910	0	20,945	Feb 14 07:13 PM
Cooke Julie	Chief Human Resources Officer	Feb 13 '25	Sale	116.78	1,551	181,129	19,544	Feb 14 07:13 PM
GORMAN KEVIN CHARLES	Director	Feb 13 '25	Option Exercise	0.00	10,979	0	527,221	Feb 14 06:57 PM
GORMAN KEVIN CHARLES	Director	Feb 13 '25	Sale	116.69	5,844	681,914	521,618	Feb 14 06:57 PM
SHERWIN STEPHEN A	Director	Feb 13 '25	Sale	116.69	13,831	1,613,923	10,673	Feb 14 06:49 PM
ROBERTS EIRY	Chief Medical Officer	Feb 13 '25	Option Exercise	0.00	4,605	0	36,140	Feb 14 06:42 PM
ROBERTS EIRY	Chief Medical Officer	Feb 13 '25	Sale	116.85	1,718	200,742	34,252	Feb 14 06:42 PM
ROBERTS EIRY	Chief Medical Officer	Feb 14 '25	Sale	115.04	500	57,521	35,640	Feb 14 06:42 PM
Onyia Jude	Chief Scientific Officer	Feb 13 '25	Option Exercise	0.00	5,407	0	19,536	Feb 14 06:35 PM
Onyia Jude	Chief Scientific Officer	Feb 13 '25	Sale	116.79	2,879	336,239	16,846	Feb 14 06:35 PM
Lippoldt Darin	Chief Legal Officer	Feb 13 '25	Option Exercise	0.00	4,100	0	44,491	Feb 14 06:26 PM
Lippoldt Darin	Chief Legal Officer	Feb 13 '25	Sale	116.75	2,184	254,992	42,474	Feb 14 06:26 PM
Gano Kyle	Chief Executive Officer	Feb 13 '25	Option Exercise	0.00	4,807	0	141,113	Feb 14 06:20 PM
Gano Kyle	Chief Executive Officer	Feb 13 '25	Sale	116.85	2,558	298,908	138,872	Feb 14 06:20 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 13 '25	Option Exercise	0.00	2,759	0	5,485	Feb 14 06:13 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 13 '25	Sale	116.71	1,471	171,674	4,084	Feb 14 06:13 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 13 '25	Option Exercise	0.00	3,352	0	4,395	Feb 14 06:08 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 13 '25	Sale	116.74	1,785	208,387	2,854	Feb 14 06:08 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 13 '25	Option Exercise	0.00	4,044	0	45,745	Feb 14 06:03 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 13 '25	Sale	116.73	2,154	251,428	43,784	Feb 14 06:03 PM
ABERNETHY MATT	Chief Financial Officer	Feb 13 '25	Option Exercise	0.00	4,807	0	37,016	Feb 14 06:00 PM
ABERNETHY MATT	Chief Financial Officer	Feb 13 '25	Sale	116.86	2,558	298,923	34,775	Feb 14 06:00 PM
EIRY WYN ROBERTS	Officer	Feb 14 '25	Proposed Sale	115.04	500	57,521		Feb 14 04:12 PM
STEPHEN A SHERWIN	Director	Feb 13 '25	Proposed Sale	117.18	13,831	1,620,717		Feb 13 04:38 PM
MATTHEW ABERNETHY	Officer	Feb 13 '25	Proposed Sale	117.18	1,352	158,427		Feb 13 04:38 PM
MATTHEW C ABERNETHY	Officer	Feb 13 '25	Proposed Sale	117.18	1,206	141,319		Feb 13 04:37 PM
KEVIN CHARLES GORMAN	Director	Feb 13 '25	Proposed Sale	117.18	3,012	352,946		Feb 13 04:37 PM
KYLE W GANO	Officer	Feb 13 '25	Proposed Sale	117.18	1,206	141,319		Feb 13 04:37 PM
JULIE SMITH COOKE	Officer	Feb 13 '25	Proposed Sale	117.18	755	88,471		Feb 13 04:37 PM
ERIC S BENEVICH	Officer	Feb 13 '25	Proposed Sale	117.18	1,056	123,742		Feb 13 04:36 PM
JUDE ONYIA	Officer	Feb 13 '25	Proposed Sale	117.18	1,447	169,559		Feb 13 04:36 PM
INGRID DELAET	Officer	Feb 13 '25	Proposed Sale	117.18	755	88,471		Feb 13 04:36 PM
DAVID WARREN BOYER	Officer	Feb 13 '25	Proposed Sale	117.18	830	97,259		Feb 13 04:35 PM
DARIN LIPPOLDT	Officer	Feb 13 '25	Proposed Sale	117.18	1,086	127,257		Feb 13 04:35 PM
EIRY WYN ROBERTS	Officer	Feb 13 '25	Proposed Sale	117.18	604	70,777		Feb 13 04:35 PM
EIRY ROBERTS	Officer	Feb 13 '25	Proposed Sale	117.18	1,114	130,539		Feb 13 04:34 PM
DARIN LIPPOLDT	Officer	Feb 13 '25	Proposed Sale	117.18	1,098	128,664		Feb 13 04:34 PM
ERIC BENEVICH	Officer	Feb 13 '25	Proposed Sale	117.18	1,098	128,664		Feb 13 04:34 PM
JUDE ONYIA	Officer	Feb 13 '25	Proposed Sale	117.18	1,432	167,802		Feb 13 04:34 PM
INGRID DELAET	Officer	Feb 13 '25	Proposed Sale	117.18	716	83,901		Feb 13 04:33 PM
DAVID WARREN BOYER	Officer	Feb 13 '25	Proposed Sale	117.18	955	111,907		Feb 13 04:33 PM
JULIE COOKE	Officer	Feb 13 '25	Proposed Sale	117.18	796	93,275		Feb 13 04:33 PM
KYLE GANO	Officer	Feb 13 '25	Proposed Sale	117.18	1,352	158,427		Feb 13 04:32 PM
Kevin Charles Gorman	Director	Feb 13 '25	Proposed Sale	117.18	2,832	331,854		Feb 13 04:31 PM
Cooke Julie	Chief Human Resources Officer	Feb 08 '25	Option Exercise	0.00	1,329	0	19,531	Feb 12 07:00 PM
Cooke Julie	Chief Human Resources Officer	Feb 10 '25	Sale	118.28	700	82,792	18,831	Feb 12 07:00 PM
GORMAN KEVIN CHARLES	Director	Feb 08 '25	Option Exercise	0.00	4,318	0	521,348	Feb 12 06:56 PM
GORMAN KEVIN CHARLES	Director	Feb 10 '25	Sale	118.37	2,274	269,167	519,074	Feb 12 06:56 PM
ROBERTS EIRY	Chief Medical Officer	Feb 08 '25	Option Exercise	0.00	1,860	0	34,233	Feb 12 06:52 PM
ROBERTS EIRY	Chief Medical Officer	Feb 10 '25	Sale	118.22	980	115,853	33,253	Feb 12 06:52 PM
Lippoldt Darin	Chief Legal Officer	Feb 08 '25	Option Exercise	0.00	1,727	0	42,590	Feb 12 06:49 PM
Lippoldt Darin	Chief Legal Officer	Feb 10 '25	Sale	118.25	911	107,727	41,679	Feb 12 06:49 PM
Gano Kyle	Chief Executive Officer	Feb 08 '25	Option Exercise	0.00	1,860	0	138,638	Feb 12 06:48 PM
Gano Kyle	Chief Executive Officer	Feb 10 '25	Sale	118.39	980	116,020	137,658	Feb 12 06:48 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 08 '25	Option Exercise	0.00	1,329	0	2,698	Feb 12 06:46 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 10 '25	Sale	118.31	700	82,820	1,998	Feb 12 06:46 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 08 '25	Option Exercise	0.00	1,860	0	43,779	Feb 12 06:44 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 10 '25	Sale	118.31	980	115,940	42,799	Feb 12 06:44 PM
ABERNETHY MATT	Chief Financial Officer	Feb 08 '25	Option Exercise	0.00	1,860	0	34,541	Feb 12 06:41 PM
ABERNETHY MATT	Chief Financial Officer	Feb 10 '25	Sale	118.27	980	115,909	33,561	Feb 12 06:41 PM
KYLE W GANO	Officer	Feb 10 '25	Proposed Sale	122.62	980	120,168		Feb 10 04:33 PM
JULIE SMITH COOKE	Officer	Feb 10 '25	Proposed Sale	122.62	700	85,834		Feb 10 04:33 PM
DAVID WARREN BOYER	Officer	Feb 10 '25	Proposed Sale	122.62	700	85,834		Feb 10 04:33 PM
ERIC BENEVICH	Officer	Feb 10 '25	Proposed Sale	122.62	980	120,168		Feb 10 04:32 PM
KEVIN CHARLES GORMAN	Director	Feb 10 '25	Proposed Sale	122.62	2,274	278,838		Feb 10 04:32 PM
DARIN LIPPOLDT	Officer	Feb 10 '25	Proposed Sale	122.62	911	111,707		Feb 10 04:32 PM
EIRY WYN ROBERTS	Officer	Feb 10 '25	Proposed Sale	122.62	980	120,168		Feb 10 04:31 PM
MATTHEW C ABERNETHY	Officer	Feb 10 '25	Proposed Sale	122.62	980	120,168		Feb 10 04:30 PM
Cooke Julie	Chief Human Resources Officer	Jan 31 '25	Option Exercise	0.00	1,740	0	19,942	Feb 04 06:05 PM
Cooke Julie	Chief Human Resources Officer	Jan 31 '25	Sale	152.89	1,740	266,025	18,202	Feb 04 06:05 PM
GORMAN KEVIN CHARLES	Director	Jan 31 '25	Option Exercise	0.00	5,141	0	519,737	Feb 04 05:58 PM
GORMAN KEVIN CHARLES	Director	Jan 31 '25	Sale	152.92	2,707	413,967	517,030	Feb 04 05:58 PM
ROBERTS EIRY	Chief Medical Officer	Jan 31 '25	Option Exercise	0.00	2,769	0	33,830	Feb 04 05:54 PM
ROBERTS EIRY	Chief Medical Officer	Jan 31 '25	Sale	152.80	1,457	222,636	32,373	Feb 04 05:54 PM

Neurocrine Biosciences, Inc

Upgrade your FINVIZ experience